Evidence map›Paper›PMID 31936504›Full record

ReviewBiomedicines2020

Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy.

Andrei A Deviatkin, Yulia A Vakulenko, Ludmila V Akhmadishina, Vadim V Tarasov, Marina I Beloukhova, Andrey A Zamyatnin, Alexander N Lukashev

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. AAV gene therapy vectors in the TMJ.Clinical and experimental dental research · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrei A DeviatkinInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia.ORCID 0000-0003-0789-4601
Yulia A VakulenkoMartsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia.
Ludmila V AkhmadishinaMartsinovsky Institute of Medical Parasitology, Tropical and Vector Borne Diseases, Sechenov First Moscow State Medical University, 119435 Moscow, Russia.
Vadim V TarasovDepartment of Pharmacology and Pharmacy, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Marina I BeloukhovaInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia.
Andrey A ZamyatninInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia.ORCID 0000-0002-3046-4565
Alexander N LukashevInstitute of Molecular Medicine, Sechenov First Moscow State Medical University, 119048 Moscow, Russia.

Funding

Ministry of Education and Science of the Russian Federation Agreement 14.605.21.0003, unique project ID RFMEFI60518X0003
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory joint disease affecting about 1% of the population worldwide. Current treatment approaches do not ensure a cure for every patient. Moreover, classical regimens are based on nontargeted systemic immune suppression and have significant side effects. Biological treatment has advanced considerably but efficacy and specificity issues remain. Gene therapy is one of the potential future directions for RA therapy, which is rapidly developing. Several gene therapy trials done so far have been of moderate success, but experimental and genetics studies have yielded novel targets. As a result, the arsenal of gene therapy tools keeps growing. Currently, both viral and nonviral delivery systems are used for RA therapy. Herein, we review recent approaches for RA gene therapy.

Indexed as

AAVCIAcircRNAclinical trialsgene deliverygene therapylncRNAmiRNAmonoclonal antibodiesrheumatoid arthritissiRNA

Identifiers

PMID31936504
PMCPMC7168286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.